The five posters will cover clinical data on the company’s DuraSite 2 platform and treatment of various ophthalmologic conditions.
The ARVO 2013 meeting will be held May 5 to 9 in Seattle.
More Articles on Ophthalmology:
FDA Grants R-Tech Ueno IND Approval for Dry Eye Treatment
Pharm-Olam, InSite Vision Complete Phase 3 Clinical Study
Glaucoma Management Lens to be Presented at ARVO 2013
